Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

Obermair called for his fellow gynecological cancer surgeons to join him in interrogating current standards of practice.

The US Food and Drug Administration yesterday approved a new indication for Rybrevant (amivantamab-vmjw), from Johnson & ...

J&J's high expectations for Rybrevant are driven mainly by its August approval with Lazcluze, which outperformed Tagrisso in ...

Global stock markets are set for a positive weekly close following the Fed’s jumbo rate cuts. The Bank of England’s hawkish ...

As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...

The AstraZeneca PLC ADR AZN inched 0.41% higher to $78.90 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index COMP rising 2.51% ...

Sunil Verma, MD, of AstraZeneca envisions the future of cancer care, including the role of AI and streamlining screening ...

For patients with limited-stage small cell lung cancer, adjuvant therapy with durvalumab leads to significantly longer ...

Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...

At a thrombosis research center, an observational study is underway investigating the impact of numerous biomarkers on ...